SS-31 (Elamipretide)

How It Works

The biology, explained.

Think of mitochondria as tiny power plants inside your cells.

Like any power plant, they depend on their internal equipment staying organized and functioning properly.

One important part of that equipment is a fatty molecule called cardiolipin.

Cardiolipin helps maintain the structure of the inner mitochondrial membrane, where much of your cellular energy production happens.

Where SS-31 comes in

SS-31 binds to cardiolipin.

Researchers have found that this interaction can help maintain mitochondrial structure and function, particularly in experimental models where mitochondria are under stress.

Three areas make this interesting:

Energy production

Mitochondria use specialized proteins to produce ATP—the molecule cells use to power their activities. SS-31 may help support the environment those proteins need to function.

Mitochondrial stability

By interacting with cardiolipin, SS-31 may help protect the organization of the mitochondrial inner membrane.

Cellular stress

Preclinical research suggests SS-31 can influence certain processes involved in oxidative stress and mitochondrial injury.

The important distinction: improving mitochondrial function in a laboratory doesn't automatically mean giving a healthy person more energy.

Go deeper: The science

SS-31 is a small peptide made of four amino-acid residues.

It interacts with cardiolipin in the inner mitochondrial membrane, an area essential for oxidative phosphorylation—the process cells use to produce ATP.

Researchers are studying how this interaction affects membrane organization, mitochondrial respiration, and responses to cellular stress.

Its established cardiolipin-binding mechanism makes SS-31 particularly interesting, but its clinical effects depend on the disease being studied.

The Evidence

What do the studies actually show?

SS-31 has been studied in humans, including randomized clinical trials.

And the results are more complicated than the excitement surrounding mitochondria might suggest.

The big milestone: Barth syndrome

Barth syndrome is a rare genetic condition that disrupts mitochondrial function and can cause muscle weakness, heart problems, fatigue, and other serious complications.

In September 2025, the FDA granted accelerated approval to Forzinity for improving muscle strength in patients with Barth syndrome weighing at least 30 kg.

The approval was based on improvements in knee-extensor muscle strength observed during longer-term treatment.

That's a meaningful milestone for a rare disease with limited treatment options.

But there's an important wrinkle.

The initial randomized trial enrolled just 12 people and did not demonstrate superiority over placebo on its main measures of walking distance and fatigue.

Muscle-strength improvements were observed later during an open-label extension, when everyone received the medication.

The FDA granted accelerated approval based on that evidence. Continued approval may depend on a confirmatory trial establishing clinical benefit.

What about other mitochondrial diseases?

A larger phase 3 trial, called MMPOWER-3, tested elamipretide in 218 people with primary mitochondrial myopathy.

After 24 weeks, the treatment did not significantly outperform placebo on the trial's main measures of walking distance or fatigue.

That's an important result.

It shows why a convincing biological mechanism doesn't guarantee a treatment will work across different conditions.

What about longevity and healthy aging?

Researchers remain interested in the relationship between mitochondria, cellular stress, and aging.

But SS-31 has not been proven to extend human lifespan, reverse biological aging, or improve energy levels in healthy adults.

The takeaway: SS-31 has a legitimate approved medical use and substantial scientific interest. Its broader longevity benefits remain unproven.

Risks & Effects

What do we know—and what don't we?

Unlike many research peptides, elamipretide has been studied in controlled human trials and has official FDA prescribing information.

That gives us a much clearer picture of its safety.

Known adverse effects

Injection-site reactions

These were the most frequent adverse reactions in clinical research.

Reported reactions included redness, discomfort, itching, bruising, swelling or firmness, and occasionally hives around the injection area.

Allergic reactions

Serious hypersensitivity is a contraindication to Forzinity. Allergic reactions require appropriate medical attention.

Changes in certain blood cells

Increases in eosinophils—a type of white blood cell—were observed during some longer studies. These changes generally resolved or returned toward baseline over time.

Important considerations

Kidney function

Elamipretide and its metabolites are eliminated through the kidneys. Severe kidney impairment can increase drug exposure, and the approved product has specific labeling for this situation.

Formulation matters

Forzinity is a regulated prescription formulation. A research vial labeled SS-31 isn't automatically equivalent in purity, concentration, sterility, or safety.

Long-term use outside approved populations

Although some clinical studies followed patients for years, we still don't have reliable long-term safety information for healthy people using SS-31 for general wellness or anti-aging.

Bottom line: There is meaningful human safety information, but it doesn't establish that unsupervised research-peptide use is safe.

Real Experiences

What are people saying?

SS-31 has attracted attention in longevity, biohacking, and mitochondrial-health communities.

Looking through public discussions, experiences are surprisingly varied.

The good

Some people describe better endurance, improved workout tolerance, clearer thinking, or feeling less exhausted during everyday activities.

Others report better sleep or an easier time completing tasks.

Interestingly, not everyone describes a noticeable burst of energy. Some report more subtle changes over time.

The not-so-good

Other users describe fatigue, jitteriness, anxiety-like sensations, increased thirst, or feeling unusually stimulated.

Some report flushing or discomfort shortly after using research products labeled SS-31.

There are also people who notice little benefit or find that the effects don't match their expectations.

The complicated

SS-31 is sometimes used alongside MOTS-c, other peptides, supplements, or changes in exercise and sleep routines.

That makes it difficult to isolate what caused a particular experience.

And because online users often obtain research products from different sources, the identity and quality of those products may vary.

So what should we believe?

The variety of experiences is interesting, particularly because some people report feeling energized while others report feeling unusually tired.

But online anecdotes can't establish how frequently these effects occur or whether SS-31 actually caused them.

The science tells us what researchers have demonstrated. The stories tell us what questions people are asking.

These summaries are drawn from real public discussions, not clinical studies. Individual reports are unverified and should not be interpreted as established effects.